The pATM Immunofluorescence assay: a high-performance radiosensitivity assay to predict post radiotherapy overreactions. - Centre de recherche en cancérologie de Lyon (UMR INSERM 1052 ; CNRS 5286 ; Centre Léon Bérard) Accéder directement au contenu
Article Dans Une Revue International Journal of Radiation Oncology, Biology, Physics Année : 2018

The pATM Immunofluorescence assay: a high-performance radiosensitivity assay to predict post radiotherapy overreactions.

Résumé

Purpose dentifying prior treatment, the patients who will overreact to radiotherapy (RT) would have sound positive clinical implications. By focusing on DNA double-strand breaks (DSB) recognition and repair proteins after irradiation, we recently demonstrated that the maximal number of pATM nuclear foci in the first hour (pATMmax) after ex vivo irradiation correlated with post-RT toxicity severity. We aimed to carry out additional analyses on our whole collection of fibroblast lines to refine the predictive performance of our assay.
Fichier principal
Vignette du fichier
Rouge_2018.pdf (131.08 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-01757771 , version 1 (03-04-2018)

Identifiants

Citer

Guillaume Vogin, Thierry Bastogne, Larry Bodgi, Julien Gillet-Daubin, Aurélien Canet, et al.. The pATM Immunofluorescence assay: a high-performance radiosensitivity assay to predict post radiotherapy overreactions.. International Journal of Radiation Oncology, Biology, Physics, 2018, 101 (3), pp.690-693. ⟨10.1016/j.ijrobp.2018.03.047⟩. ⟨hal-01757771⟩
408 Consultations
558 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More